Key result
Bivalirudin carries ~27% bleeding risk and frequent thrombosis in critically ill children despite therapeutic levels.
Why the study?
Data on bivalirudin for the treatment or prevention of venous or arterial thromboses in children are limited.
What are the rates of bleeding and thrombotic events associated with bivalirudin use in critically ill children?
Observational (n=229)
No
What are the rates of bleeding and thrombotic events associated with bivalirudin use in critically ill children?
In critically ill children, bivalirudin rapidly achieves therapeutic levels but is associated with frequent bleeding and thrombotic events, warranting close monitoring.
Answers are grounded in this paper and cite their sources.
Supports bivalirudin as a potential alternative anticoagulant in critically ill children; leaves.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bashir et al. (2026) conducted an observational in Critically ill children requiring anticoagulation for venous and/or arterial thromboses (n=229). Bivalirudin was evaluated on bleeding and thrombotic events. Bivalirudin use in critically ill children was associated with bleeding in 27% of patients and thrombotic events in 16% of patients, despite frequently achieving therapeutic ranges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: